Cargando…

US FDA’s Assessment of the Benefit-risk of Cefiderocol for its Initial Complicated Urinary Tract Infection Indication

Detalles Bibliográficos
Autores principales:	Echols, Roger M, Nagata, Tsutae
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366820/ https://www.ncbi.nlm.nih.gov/pubmed/34398951 http://dx.doi.org/10.1093/cid/ciab010

Ejemplares similares

666. Efficacy and Safety of Cefiderocol According to Renal Impairment in Patients With Complicated Urinary Tract Infection (cUTI) in a Phase 2 Study
por: Portsmouth, Simon, et al.
Publicado: (2019)

Pathogen-focused Clinical Development to Address Unmet Medical Need: Cefiderocol Targeting Carbapenem Resistance
por: Echols, Roger, et al.
Publicado: (2019)

Structured patient interview to assess clinical outcomes in complicated urinary tract infections in the APEKS-cUTI study: pilot investigation
por: Portsmouth, Simon, et al.
Publicado: (2021)

The effects of lobbying on the FDA’s recall classification
por: Zhou, Yifan
Publicado: (2023)

1473. Structured Patient Interview in Complicated Urinary Tract Infections to Assess Clinical Outcomes vs. Investigator’s Evaluation in the APEKS-cUTI Study
por: Portsmouth, Simon, et al.
Publicado: (2019)

LB4. Efficacy and Safety of Cefiderocol vs. High-Dose Meropenem in Patients with Nosocomial Pneumonia—Results of a Phase 3, Randomized, Multicenter, Double-Blind, Non-Inferiority Study
por: Wunderink, Richard G, et al.
Publicado: (2019)

FDA’s new pharmaceutical quality initiative: Knowledge-aided assessment & structured applications
por: Yu, Lawrence X., et al.
Publicado: (2019)

1266. Characterization of Shifts in Minimum Inhibitory Concentrations During Treatment with Cefiderocol or Comparators in the Phase 3 CREDIBLE-CR and APEKS-NP Studies
por: Takemura, Miki, et al.
Publicado: (2020)

Physician Perceptions of the FDA’s Breakthrough Therapy Designation: An Update
por: Paquin, Ryan S, et al.
Publicado: (2022)

1269. Differences in Interpretative Breakpoints Between CLSI, FDA and EUCAST Impact Reporting of Susceptibility and Resistance to Cefiderocol
por: Yamano, Yoshinori, et al.
Publicado: (2020)

Medical device risk (re)classification: lessons from the FDA’s 515 Program Initiative
por: Mooghali, Maryam, et al.
Publicado: (2023)

Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients with Pneumonia, Bloodstream Infection/Sepsis, or Complicated Urinary Tract Infection
por: Kawaguchi, Nao, et al.
Publicado: (2021)

Translating New Science Into the Drug Review Process: The US FDA’s Division of Applied Regulatory Science
por: Rouse, Rodney, et al.
Publicado: (2017)

Evaluating adverse effects of environmental agents in food: a brief critique of the US FDA’s criteria
por: Vandenberg, Laura N., et al.
Publicado: (2023)

1316. Pharmacokinetic/Pharmacodynamic Analyses of Cefiderocol in Critically Ill Patients
por: Katsube, Takayuki, et al.
Publicado: (2020)

Comment on ‘Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety’
por: Koren, Andrew, et al.
Publicado: (2021)

LAWS, REGULATIONS, AND POLICY: Genetically Engineered Salmon on the FDA’s Table
por: Taylor, David A.
Publicado: (2010)

The FDA’s Experience with Emerging Genomics Technologies—Past, Present, and Future
por: Xu, Joshua, et al.
Publicado: (2016)

FDA’s tracking and analysis of surveillance sampling isolates for outbreak detection
por: Blessington, Tyann, et al.
Publicado: (2017)

The FDA’s Regulatory Framework for Chimeric Antigen Receptor‐T Cell Therapies
por: Marks, Peter
Publicado: (2019)

Public perceptions of the FDA’s marketing authorization of Vuse on Twitter/X
por: Lee, Sarah, et al.
Publicado: (2023)

165. Cefiderocol Treatment for Serious Infections Caused by Carbapenem-resistant Bacteria: Post-hoc Analysis of Outcomes by Pathogen in the CREDIBLE-CR Study
por: Matsunaga, Yuko, et al.
Publicado: (2020)

OpenFDA: an innovative platform providing access to a wealth of FDA’s publicly available data
por: Kass-Hout, Taha A, et al.
Publicado: (2016)

1302. Cefiderocol Population Pharmacokinetics and Probability of Target Attainment in Plasma and Epithelial Lining Fluid in Patients with Pneumonia, Bloodstream Infection/Sepsis, or Complicated Urinary Tract Infections
por: Katsube, Takayuki, et al.
Publicado: (2020)

1292. Safety Profile of the Novel Siderophore Cephalosporin Cefiderocol in Randomized Phase 2 and Phase 3 Clinical Studies of Serious Gram-Negative Infections
por: Matsunaga, Yuko, et al.
Publicado: (2020)

COVID-19 emergency responders in FDA’s Center for Drug Evaluation and Research
por: Gormley, Lieutenant Commander Andrea, et al.
Publicado: (2020)

FDA’s Strategies to Close the Health Equity Gap among Diverse Populations
por: Spinner, Jovonni, et al.
Publicado: (2021)

Awareness of and receptivity to FDA’s point-of-sale tobacco public education campaign
por: Dutra, Lauren M., et al.
Publicado: (2023)

Population Pharmacokinetic Analysis of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Healthy Subjects, Subjects with Various Degrees of Renal Function, and Patients with Complicated Urinary Tract Infection or Acute Uncomplicated Pyelonephritis
por: Kawaguchi, Nao, et al.
Publicado: (2018)

Industrial Perspective on the Benefits Realized From the FDA’s Model‐Informed Drug Development Paired Meeting Pilot Program
por: Galluppi, Gerald R., et al.
Publicado: (2021)

Combating antimicrobial resistance with cefiderocol for complicated infections involving the urinary tract
por: Wang, Hongmei, et al.
Publicado: (2022)

Regulation of immunotherapeutic products for cancer and FDA’s role in product development and clinical evaluation
por: Vatsan, Ramjay S, et al.
Publicado: (2013)

Physicians’ Trust in the FDA’s Use of Product-Specific Pathways for Generic Drug Approval
por: Kesselheim, Aaron S., et al.
Publicado: (2016)

WITHDRAWN: COVID-19 Emergency Responders in FDA’s Center for Drug Evaluation and Research
por: Gormley, LCDR Andrea, et al.
Publicado: (2020)

A Critical Analysis of the FDA’s Omics-Driven Pharmacodynamic Biomarkers to Establish Biosimilarity
por: Niazi, Sarfaraz K.
Publicado: (2023)

A Call to Action to Track Generic Drug Quality Using Real-World Data and the FDA’s Sentinel Initiative
por: Brown, Joshua D.
Publicado: (2020)

A Retrospective Review of Center for Biologics Evaluation and Research Advisory Committee Meetings in the Context of the FDA’s Benefit-Risk Framework
por: Mutanga, Jane Namangolwa, et al.
Publicado: (2023)

2163. Risk Factors for Carbapenem-Resistant Gram-Negative Bloodstream Infections (BSI) in U.S. Hospitals (2010–2015)
por: Cai, Bin, et al.
Publicado: (2018)

1271. Efficacy and Safety of Cefiderocol and Best Available Therapy in Patients with Serious Infections Caused by Carbapenem-Resistant Gram-Negative Infections: Results of the Pathogen-Focused Phase 3 CREDIBLE-CR Study
por: Bassetti, Matteo, et al.
Publicado: (2020)

FDA’s Nozzle Numerical Simulation Challenge: Non-Newtonian Fluid Effects and Blood Damage
por: Trias, Miquel, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_vs8f8k9rl0cffptsp4u2u74jn1